Proceedings of the National Academy of Sciences of the United States of America 112, 87688773 (2015)
Krishnan, A., Hadi, Y., Hutson, W
In the SURPASS clinical trial programme, patients saw HbA1c reductions of up to 2.3 percentage points on average, with many reaching blood sugar levels comparable to people without diabetes - -results that consistently outperformed GLP-1-only medications, DPP-4 inhibitors, and some forms of insulin
Katherine Saunders, MD, co-founder of FlyteHealth and obesity medicine specialist at Weill Cornell Medicine in New York City, explains, The lack of coverage, high cost, and drug shortages are tremendous barriers to tirzepatide access right now, so many patients ask about compounded medications. However, that doesnt mean it is safe or even legal
Doupis et al
Consoli, V., Sorrenti, V., Grosso, S